Doxazosin in metabolically complicated hypertension

References

• Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet364, 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO consultation, definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. World Health Organisation, Geneva, Switzerland (1999).
   Google Scholar
• Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med.16, 442–443 (1999).
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet366, 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care28, 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet365, 1415–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Borghi C et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J. Hypertens.24, 837–843 (2006).
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J. Am. Coll. Cardiol.43, 1817–1822 (2004).
   PubMed Web of Science ®Google Scholar
• Miccoli R, Bianchi C, Odoguardi L et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr. Metab. Cardiovasc. Dis.15, 250–254 (2005).
   PubMed Web of Science ®Google Scholar
• Leoncini G, Ratto E, Viazzi F et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med.257, 454–460 (2005).
   PubMed Web of Science ®Google Scholar
• Dell’Omo G, Penno G, Pucci L, Mariani M, Del Prato S, Pedrinelli R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid metabolic syndrome. Atherosclerosis172, 383–389 (2004).
   PubMedGoogle Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens. Res.29, 839–847 (2006).
   Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type II diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342, 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis.17, 319–326 (2007).
   PubMed Web of Science ®Google Scholar
• Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R. Treating the metabolic syndrome. Expert Rev. Cardiovasc. Ther.5, 491–506 (2007).
   PubMedGoogle Scholar
• Campbell SF, Davey MJ. Doxazosin, a case history. Drug Des. Deliv.1, 83–99 (1986).
   PubMedGoogle Scholar
• Steers WD, Kirby RS. Clinical ease of using doxazosin in BPH patients with and without hypertension. Prostate Cancer Prostatic Dis.8, 152–157 (2005).
   PubMedGoogle Scholar
• Starke K. Presynaptic autoreceptors in the third decade: focus on α2-adrenoceptors. J. Neurochem.78, 685–693 (2001).
   PubMedGoogle Scholar
• Sica D. Α 1-adrenergic blockers: current usage considerations. J. Clin. Hypertens.7, 757–762 (2005).
   PubMedGoogle Scholar
• Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation91, 698–706 (1995).
   PubMed Web of Science ®Google Scholar
• Giordano M, Sanders LR, Castellino P, Canessa ML, DeFronzo RA. Effect of α-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron72, 447–453 (1996).
   PubMedGoogle Scholar
• Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension21, 810–815 (1993).
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA270, 713–724 (1993).
   PubMed Web of Science ®Google Scholar
• Bryson CL, Psaty BM. A review of the adverse effects of peripheral α-1 antagonists in hypertension therapy. Curr. Control Trials Cardiovasc. Med.3, 7 (2002).
   PubMedGoogle Scholar
• Fernando MA, Heaney AP. α 1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol. Endocrinol.19, 3085–3096 (2005).
   PubMed Web of Science ®Google Scholar
• Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr. Urol. Rep.7, 288–292 (2006).
   PubMedGoogle Scholar
• Garcia-Sainz JA, Vazquez-Prado J, del Carmen Medina L. α 1-adrenoceptors: function and phosphorylation. Eur. J. Pharmacol.389, 1–12 (2000).
   PubMedGoogle Scholar
• Chu CA, Sindelar DK, Igawa K et al. The direct effects of catecholamines on hepatic glucose production occur via α(1)-and β(2)-receptors in the dog. Am. J. Physiol. Endocrinol. Metab.279, E463–E473 (2000).
   Google Scholar
• Deshaies Y, Belahsen R. Postprandial plasma triacylglycerols in rats under α 1-adrenergic blockade. Am. J. Physiol.264, E541–E547 (1993).
   Google Scholar
• D’Eletto RD, Javitt NB. Effect of doxazosin on cholesterol synthesis in cell culture. J. Cardiovasc. Pharmacol.13(Suppl. 2), S1–S4 (1989).
   PubMedGoogle Scholar
• Cox DA, Leader JP, Milson JA, Singleton W. The antihypertensive effects of doxazosin: a clinical overview. Br. J. Clin. Pharmacol.21(Suppl, 1), 83S–90S (1986).
   PubMed Web of Science ®Google Scholar
• Grimm RH. α 1-antagonists in the treatment of hypertension. Hypertension13(Suppl.), I131–I136 (1989).
   Google Scholar
• Glanz M, Garber AJ, Mancia G, Levenstein M. Meta-analysis of studies using selective α1-blockers in patients with hypertension and Type II diabetes. Int. J. Clin. Pract.55, 694–701 (2001).
   PubMedGoogle Scholar
• Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J. Hypertens.9, 323–333 (1996).
   PubMed Web of Science ®Google Scholar
• Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin. Ther.15, 829–837 (1993).
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Shiba Y, Sekiya M et al. Selective α 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension. J. Hum. Hypertens.8, 555–558 (1994).
   PubMedGoogle Scholar
• Giorda C, Appendino M, Mason MG, Imperiale E, Pagano G. α 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism44, 673–676 (1995).
   PubMedGoogle Scholar
• Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes44, 665–671 (1995).
   PubMed Web of Science ®Google Scholar
• Jeng JR, Sheu WH, Jeng CY, Huang SH, Shieh SM. Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. Am. Heart J.132, 783–789 (1996).
   PubMedGoogle Scholar
• Courtney CH, McCance DR, Atkinson AB et al. Effect of the α-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism52, 1147–1152 (2003).
   PubMedGoogle Scholar
• Ueshiba H, Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm. Metab. Res.35, 532–536 (2003).
   PubMedGoogle Scholar
• Derosa G, Cicero AF, D’Angelo A et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin. Drug Investig.26, 529–539 (2006).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with Type II diabetes and hypertension. J. Cardiovasc. Pharmacol.45, 599–604 (2005).
   PubMedGoogle Scholar
• Yildiz A, Hursit M, Celik AV et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin. Nephrol.58, 405–410 (2002).
   PubMedGoogle Scholar
• Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin–angiotensin systems. Naunyn Schmiedebergs Arch. Pharmacol.373, 245–258 (2006).
   PubMedGoogle Scholar
• Zehetgruber M, Christ G, Gabriel H et al. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. Thromb. Haemost.79, 378–382 (1998).
   PubMed Web of Science ®Google Scholar
• Pasanisi F, Imperatore G, Vaccaro O, lovine C, Ferrara LA. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in Type 2 diabetic patients with hypertension. Nutr. Metab. Cardiovasc. Dis.9, 73–77 (1999).
   PubMedGoogle Scholar
• Fliser D, Nowack R, Allendorf-Ostwald N, Kohl B, Hubinger A, Ritz E. Serum lipid changes on low salt diet. Effects of α 1-adrenergic blockade. Am. J. Hypertens.6, 320–324 (1993).
   PubMedGoogle Scholar
• Hobbs FR, Khan T, Collins B. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. Br. J. Gen. Pract.55, 437–443. (2005).
   PubMedGoogle Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Differential effects of β-blockers on albuminuria in patients with Type II diabetes. Hypertension46, 1309–1315 (2005).
   PubMedGoogle Scholar
• Dell’Omo G, Penno G, Pucci L et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron. Artery Dis.16, 67–73 (2005).
   PubMedGoogle Scholar
• Folkow B. Physiological aspects of primary hypertension. Physiol. Rev.62, 347–504 (1982).
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Caglar K et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology12, 147–153 (2007).
   PubMed Web of Science ®Google Scholar
• Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am. J. Hypertens.14, 908–913 (2001).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, D’Angelo A et al. Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. J. Cardiovasc. Pharmacol.47, 508–512 (2006).
   PubMedGoogle Scholar
• Fukuzawa M, Satoh J, Ohta S et al. Modulation of tumor necrosis factor-α production with anti-hypertensive drugs. Immunopharmacology48, 65–74 (2000).
   PubMed Web of Science ®Google Scholar
• Demirtunc R, Duman D, Basar M. Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Clin. Drug Investig.27, 435–441 (2007).
   Google Scholar
• Opie LH, Schall R. Old antihypertensives and new diabetes. J. Hypertens.22, 1453–1458 (2004).
   PubMed Web of Science ®Google Scholar
• Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation115, 1991–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• Bernobich E, de Angelis L, Lerin C, Bellini G. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs62, 1295–1314 (2002).
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369, 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Gerstein HC et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355, 1551–1562 (2006).
   PubMed Web of Science ®Google Scholar
• ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone; the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA283, 1967–1975 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation113, 2851–2860 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch. Intern. Med.167, 490–496 (2007).
   PubMedGoogle Scholar
• Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in α-blocker prescribing. JAMA291, 54–62 (2004).
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.166, 2191–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar